NovaBridge Announces Open Market Purchases by Executive Chairman, Fu Wei
Rhea-AI Summary
NovaBridge (Nasdaq: NBP) announced that Executive Chairman Fu Wei intends to purchase up to $5,000,000 of the company’s American Depository Shares (ADSs) in open‑market transactions. The purchases began on January 15, 2026 and were ongoing as of January 20, 2026. The planned purchases are being executed via an entity controlled by Fu Wei, and the company stated it cannot guarantee the number of ADSs to be purchased or the time frame for purchases. The announcement referenced positive Phase 1b dose expansion data for givastomig in first‑line metastatic gastric cancer and framed the insider purchases as tied to confidence in the company’s clinical progress and strategy.
Positive
- Executive Chairman intends to purchase up to $5,000,000 of ADSs
- Purchases commenced on January 15, 2026 and are ongoing as of the announcement
Negative
- Company cannot guarantee the number of ADSs to be purchased or the time frame for purchases
News Market Reaction – NBP
In the Jan 20 session, NBP gained 5.09%, reflecting a notable positive market reaction. Argus tracked a peak move of +5.4% during that session. Our momentum scanner triggered 15 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 06 | Clinical data update | Positive | -11.2% | Updated Phase 1b givastomig gastric cancer efficacy and safety data. |
| Dec 30 | Index inclusion | Positive | -1.7% | Nasdaq opening bell event and inclusion in the Nasdaq Biotech Index. |
| Dec 10 | Clinical data update | Positive | +1.7% | Positive ragistomig Phase 1 dose‑expansion data and safety profile at ESMO‑IO. |
| Dec 03 | Clinical data preview | Positive | +4.9% | Announcement of upcoming ragistomig Phase 1 data presentation at ESMO‑IO. |
| Nov 20 | Management change | Positive | -7.5% | Key ophthalmology leadership appointments to advance VIS-101 toward Phase 3 readiness. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has generally been positive, but price reactions skew negative, with three notable selloffs on favorable clinical and corporate updates.
Over the last few months, NovaBridge reported multiple positive clinical and corporate milestones. On Nov 20, 2025, new ophthalmology leadership for VIS-101 preceded a -7.51% move. Two ragistomig Phase 1 updates in early December showed encouraging efficacy and safety, with mixed price reactions of +4.94% and +1.74%. Entry into the Nasdaq Biotech Index on Dec 19, 2025 and strong givastomig Phase 1b data on Jan 6, 2026 both saw negative follow‑through, including a -11.21% drop. Today’s insider purchase plan arrives after this pattern of selling into good news.
Key Terms
phase 1b medical
metastatic medical
first line (1l) medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Executive Chairman of the Board, Fu Wei, informed the Company of his intent to purchase up to
ROCKVILLE, Md., Jan. 20, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines, today announced that Fu Wei, Executive Chairman of the Board, intends to purchase up to
“2025 was a defining year for NovaBridge as we executed a new business strategy and built a truly global platform. This, combined with compelling Phase 1b dose expansion data for givastomig, reinforces our conviction in the strength of our clinical development capabilities, efficient execution, and long-term potential. We believe we are well-positioned for the next phase of growth, and I remain deeply confident in our team’s ability to create meaningful value for patients and shareholders alike,” said Fu Wei, Executive Chairman of NovaBridge and Chief Executive Officer of CBC Group.
NovaBridge recently announced positive givastomig dose expansion data from the Phase 1b combination study in patients with first line (1L) metastatic gastric cancer.
About NovaBridge
NovaBridge is a global biotechnology platform company committed to accelerating access to innovative medicines. The Company combines deep business development expertise with agile translational clinical development to identify, accelerate, and advance breakthrough assets. By bridging science, strategy, and execution, NovaBridge enables transformative therapies to progress rapidly from discovery toward patients in need.
The Company’s differentiated pipeline is led by givastomig, a potential best-in-class, Claudin 18.2 x 4-1BB bispecific antibody, and VIS-101, a second-in-class, potentially best-in-class bifunctional biologic, targeting VEGF-A and ANG2.
Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed to treat Claudin 18.2-positive gastric cancer and other gastrointestinal malignancies. The Company is also collaborating with its partner, ABL Bio, for the development of ragistomig, a bispecific antibody integrating PD-L1 as a tumor engager and 4-1BB as a conditional T cell activator, in solid tumors. Additionally, NovaBridge owns worldwide rights outside of China to uliledlimab, an anti-CD73 antibody that targets adenosine-driven immunosuppression in cancer.
VIS-101 targets VEGF-A and ANG-2 to provide more potent and durable treatment benefits for patients with wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). VIS-101 is currently completing a large, randomized, dose-ranging Phase 2 study for wet AMD. NovaBridge is the majority shareholder of Visara, and Visara controls global rights to VIS-101, outside of Greater China and certain countries in Asia.
For more information, please visit www.novabridge.com and follow us on LinkedIn.
Forward Looking Statements
This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will”, “expects”, “believes”, “designed to”, “anticipates”, “future”, “intends”, “plans”, “potential”, “estimates”, “confident”, and similar terms or the negative thereof. NovaBridge may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the SEC), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements in this press release include, without limitation, statements regarding: the potential open market purchases by Fu Wei; the strategy, clinical development, plans, results, safety and efficacy of givastomig and VIS-101 and its other drug candidates; the strategic and clinical development of NovaBridge’s drug candidates, including givastomig, ragistomig, uliledlimab, and VIS-101; anticipated clinical milestones and results, and related timing. Forward-looking statements involve inherent risks and uncertainties that may cause actual results to differ materially from those contained in these forward-looking statements, including but not limited to the following: prevailing market conditions; the Company’s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may or may not support further development or New Drug Application/Biologics License Application (NDA/BLA) approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of the Company’s drug candidates; the Company’s ability to achieve commercial success for its drug candidates, if approved; the Company’s ability to obtain and maintain protection of intellectual property for its technology and drugs; the Company’s reliance on third parties to conduct drug development, manufacturing and other services; the Company’s limited operating history and the Company’s ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; and those risks more fully discussed in the “Risk Factors” section in the Company’s annual report on Form 20-F filed with the SEC on April 3, 2025 as well as the discussions of potential risks, uncertainties, and other important factors in the Company’s subsequent filings with the SEC. All forward-looking statements are based on information currently available to the Company. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law.
NovaBridge Investor & Media Contacts
PJ Kelleher
LifeSci Advisors
+1-617-430-7579
pkelleher@lifesciadvisors.com
NovaBridge Biosciences
+1-240-745-6330
IR@novabridge.com
